Regular treatment with formoterol for chronic asthma: Serious adverse events

Cochrane Database of Systematic Reviews

Volumn , Issue 1, 2008, Pages

  Cates, Christopher J ^a   Cates, M J ^b   Lasserson, T ^b  

^a ST GEORGE S HOSPITAL   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE PLUS FORMOTEROL; CORTICOSTEROID DERIVATIVE; FLUTICASONE PROPIONATE PLUS SALMETEROL; FORMOTEROL; LEUKOTRIENE RECEPTOR STIMULATING AGENT; LONG ACTING DRUG; SALMETEROL; SALMETEROL XINAFOATE; SHORT ACTING DRUG; STEROID; THEOPHYLLINE; BECLOMETASONE; BECLOMETASONE DIPROPIONATE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; BUDESONIDE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CHROMONE DERIVATIVE; CORTICOSTEROID; CROMOGLYCATE DISODIUM; FLUNISOLIDE; FLUTICASONE; FLUTICASONE PROPIONATE; LEUKOTRIENE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; METHACHOLINE; METHYLXANTHINE DERIVATIVE; PLACEBO; PREDNISONE; SALBUTAMOL; TRIAMCINOLONE; TRIAMCINOLONE ACETONIDE; UNINDEXED DRUG; ADRENALIN; FENOTEROL; ISOPRENALINE; MONTELUKAST; TERBUTALINE; TERBUTALINE SULFATE; ANTIASTHMATIC AGENT; DRUG DERIVATIVE;

ASTHMA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DATA EXTRACTION; DIAGNOSTIC PROCEDURE; DISEASE SEVERITY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; INFORMATION PROCESSING; INTERVENTION STUDY; MORTALITY; REVIEW; RISK FACTOR; TREATMENT OUTCOME; ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ADENOCARCINOMA; ANEMIA; ASTHMATIC STATE; BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONFIDENCE INTERVAL; CONGESTIVE HEART FAILURE; COUGHING; DEEP VEIN THROMBOSIS; DEPRESSION; DISEASE EXACERBATION; DIVERTICULITIS; DIZZINESS; DRUG DOSE REDUCTION; EVENING DOSAGE; FEMUR FRACTURE; FEVER; GASTROINTESTINAL HEMORRHAGE; GLIOMA; HEART DISEASE; KNEE LIGAMENT INJURY; LEG INJURY; MONONUCLEOSIS; RESPIRATORY TRACT DISEASE; RESPIRATORY TRACT INFECTION; RISK; SIDE EFFECT; SYSTEMATIC REVIEW; TONSILLITIS; TRANSIENT ISCHEMIC ATTACK; TREATMENT DURATION; WEIGHT REDUCTION; APPENDICITIS; ASTHMA EXACERBATION; BASAL CELL CARCINOMA; CORONARY ARTERY OBSTRUCTION; DRUG DELIVERY SYSTEM; DRUG DOSE COMPARISON; DRUG INDUCED CANCER; DRUG MEGADOSE; DRY POWDER; EATING DISORDER; FOOD AND DRUG ADMINISTRATION; HEART RATE; HEMATURIA; LOW DRUG DOSE; LUNG SMALL CELL CANCER; META ANALYSIS; NEPHROLITHIASIS; OUTCOME ASSESSMENT; OUTCOME VARIABLE; PEAK EXPIRATORY FLOW; PNEUMONIA; RISK ASSESSMENT; THERAPY EFFECT; TREATMENT WITHDRAWAL; ADULT; CAUSE OF DEATH; CHILD; RANDOMIZED CONTROLLED TRIAL;

ADRENERGIC BETA-AGONISTS; ADULT; ALBUTEROL; ANTI-ASTHMATIC AGENTS; ASTHMA; BRONCHODILATOR AGENTS; CAUSE OF DEATH; CHILD; HUMANS; PLACEBOS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 44949194776     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD006923     Document Type: Review

References (240)

1. Bensch G, Lapidus RJ, Levine BE, Lumry W, Yegen U, Kiselev P, et al. A randomized, 12-week, double-blind, placebo-controlled study comparing formoterol dry powder inhaler with albuterol metered-dose inhaler. Annals of Allergy, Asthma, and Immunology 2001; Vol. 86, issue 1: 19–27.
2. Mann M, Chowdhury B, Sullivan E, Nicklas R, Anthracite R, Meyer RJ. Serious asthma exacerbations in asthmatics treated with high-dose formoterol. Chest 2003; Vol. 124, issue 1:70–4.
3. Novartis. A twelve-week, double-blind, parallel group trial comparing the safety, tolerability and efficacy of formoterol dry powder capsules for inhalation delivered by a singledose inhaler versus albuterol metered-dose inhaler (MDI) versus placebo in patients with mild to moderate asthma. FDA Application 20-831 (Trial reference 040) Accessed 2 June 2008. [http://www.fda.gov/cder/foi/nda/2001/20831˙Foradil˙medr˙P1.pdf]
4. Bensch G, Berger WE, Blokhin BM, Socolovsky AL, Thomson MH, Till MD, et al. One-year efficacy and safety of inhaled formoterol dry powder in children with persistent asthma. Annals of Allergy, Asthma and Immunology 2002; Vol. 89, issue 2:180–90.
5. Mann M, Chowdhury B, Sullivan E, Nicklas R, Anthracite R, Meyer RJ. Serious asthma exacerbations in asthmatics treated with high-dose formoterol. Chest 2003; Vol. 124, issue 1:70–4.
6. Novartis. A twelve-month, double-blind, between patient placebo controlled trial comparing the safety, tolerability and efficacy of 12 mcg and 24 mcg twice daily dry powder capsules for inhalation delivered by a single-dose inhaler (AerolizerTM) in children with asthma in need of daily treatment with inhaled bronchodilators and antiinflammatory treatment. FDA Application 20-831 (Trial reference 049) Accessed 2 June 2008. [http://www.fda.gov/cder/foi/nda/2001/20831˙Foradil˙medr˙P1.pdf]
7. Busse W, Levine B, Andriano K, Lavecchia C, Yegen U. Efficacy, tolerability, and effect on asthma-related quality of life of formoterol BID via multidose dry powder inhaler and albuterol QID via metered dose inhaler in patients with persistent asthma: a multicenter, randomized, double-blind, double-dummy, placebo-controlled, parallel-group study. Clinical Therapeutics 2004; Vol. 26, issue 10:1587–98.
8. AstraZeneca. SD-039-0716. A twelve-week, randomized, double-blind, double-dummy, placebo-controlled trial of SYMBICORT® pMDI (80/4.5 μg) versus its monoproducts (budesonide and formoterol) in children (≥ 6 years of age) and adults with asthma - SPRUCE 80/4.5. http://www.astrazenecaclinicaltrials.com/sites/133/imagebank/typeArticleparam528362/SD-039-0716.pdf Accessed November 2008.
9. Corren J, Korenblat PE, Miller CJ, O’Brien CD, Mezzanotte WS. Twelve-week, randomized, placebocontrolled, multicenter study of the efficacy and tolerability of budesonide and formoterol in one metered-dose inhaler compared with budesonide alone and formoterol alone in adolescents and adults with asthma. Clinical Therapeutics 2007; Vol. 29, issue 5:823–43.
10. Ekstrom T, Ringdal N, Sobradillo V, Runnerstrom E, Soliman S. Low-dose formoterol Turbuhaler Oxis b.i.d., a 3-month placebo-controlled comparison with terbutaline q.i.d. Respiratory Medicine 1998; Vol. 92, issue 8:1040–5.
11. Ekstrom T, Ringdal N, Tukiainen P, Runnerstrom E, Soliman S. A 3-month comparison of formoterol with terbutaline via turbuhaler. A placebo-controlled study. Annals of Allergy 1998; Vol. 81, issue 3:225–30.
12. FitzGerald JM, Chapman KR, Della Cioppa G, Stubbing D, Fairbarn MS, Till MD, et al. Sustained bronchoprotection, bronchodilatation, and symptom control during regular formoterol use in asthma of moderate or greater severity. Journal of Allergy and Clinical Immunology 1999; Vol. 103, issue 3 I:427–35.
13. Hekking PR, Maesen F, Greefhorst A, Prins J, Tan Y, Zweers P. Long-term efficacy of formoterol compared to salbutamol. Lung 1990; Vol. 168, issue Suppl 1:76–82.
14. Kesten S, Chapman KR, Broder I, Cartier A, Hyland RH, Knight A, et al. A three-month comparison of twice daily inhaled formoterol versus four times daily inhaled albuterol in the management of stable asthma. American Review of Respiratory Disease 1991; Vol. 144, issue 3 Pt 1:622–5.
15. Sculpher MJ, Buxton MJ. The episode-free day as a composite measure of effectiveness: an illustrative economic evaluation of formoterol versus salbutamol in asthma therapy [see comments]. Pharmacoeconomics 1993; Vol. 4, issue 5:345–52.
16. Kozlik-Feldmann R, von Berg A, Berdel D, Reinhardt D. Long-term effects of formoterol and salbutamol on bronchial hyperreactivity and beta-adrenoceptor density on lymphocytes in children with bronchial asthma. European Journal of Medical Research 1996; Vol. 1, issue 10:465–70.
17. LaForce C, Prenner BM, Andriano K, Lavecchia C, Yegen U. Efficacy and safety of formoterol delivered via a new multidose dry powder inhaler (Certihaler) in adolescents and adults with persistent asthma. Journal of Asthma 2005; Vol. 42, issue 2:101–6.
18. Levy R, Pinnas J, Milgrom H, Smith J, Yegen U. Safety and efficacy in children with persistent asthma treated with formoterol 10 mug BID delivered via Certihaler: a novel multidose dry-powder inhaler. Pediatric Asthma Allergy & Immunology 2005; Vol. 18, issue 1:25–35.
19. Molimard M, Bourcereau J, Le Gros V, Bourdeix I, Leynadier F, Duroux P, et al. Comparison between formoterol 12 microg b.i.d. and on-demand salbutamol in moderate persistent asthma. Respiratory Medicine 2001; Vol. 95, issue 1:64–70.
20. Noonan M, Rosenwasser LJ, Martin P, O’Brien CD, O’Dowd L. Efficacy and safety of budesonide and formoterol in one pressurised metered-dose inhaler in adults and adolescents with moderate to severe asthma: a randomised clinical trial. Drugs 2006; Vol. 66, issue 17: 2235–54.
21. Novartis. Pulmonary-Allergy Drugs Advisory Committee on the safety of long-acting beta-agonist bronchodilators NDA 20-831 Briefing Document. http://www.fda.gov/ohrms/dockets/AC/05/briefing/2005-4148B1˙02˙01-Novartis-Foradil.pdf Accessed July 2008.
22. Mann M, Chowdhury B, Sullivan E, Nicklas R, Anthracite R, Meyer RJ. Serious asthma exacerbations in asthmatics treated with high-dose formoterol. Chest 2003; Vol. 124, issue 1:70–4.
23. Novartis. A twelve-week, double-blind, parallel group trial comparing the safety, tolerability and efficacy of formoterol dry powder capsules for inhalation delivered by a singledose inhaler versus albuterol metered-dose inhaler (MDI) versus placebo in patients with mild to moderate asthma. FDA Application 20-831 (Trial reference 041) Accessed 2 June 2008. [http://www.fda.gov/cder/foi/nda/2001/20831˙Foradil˙medr˙P1.pdf]
24. Pleskow W, LaForce CF, Yegen U, Matos D, Della Cioppa G. Formoterol delivered via the dry powder Aerolizer inhaler versus albuterol MDI and placebo in mild-to-moderate asthma: a randomized, double-blind, double-dummy trial. Journal of Asthma 2003; Vol. 40, issue 5:505–14.
25. AstraZeneca. A 3-month, multi-centre, double-blind, double-dummy, randomised, parallel group, phase III study to investigate the efficacy and safety of formoterol HFA pMDI compared with placebo and Oxis Turbuhaler in subjects with asthma. www.astrazenecaclinicaltrials.com/Article/515841.aspx Accessed 19 June 2008.
26. ® in subjects with asthma. www.astrazenecaclinicaltrials.com/sites/133/imagebank/typeArticleparam528785/D5125C00344.pdf Accessed 19 June 2008.
27. Steffensen I, Faurschou P, Riska H, Rostrup J, Wegener T. Inhaled formoterol dry powder in the treatment of patients with reversible obstructive airway disease. A 3-month, placebo-controlled comparison of the efficacy and safety of formoterol and salbutamol, followed by a 12-month trial with formoterol. Allergy 1995; Vol. 50, issue 8:657–63.
28. Steffensen IE, Faurschou P. Formoterol as inhalation powder in the treatment of patients with reversible obstructive lung diseases. A 3-month placebo-controlled comparison of the effects of formoterol and salbutamol, followed by a 12-month period with formoterol alone. Ugeskrift for Laeger 1996; Vol. 158, issue 49:7092–6.
29. van der Molen T. Formoterol and asthma exacerbations [5]. Chest 2004; Vol. 125, issue 4:1591.
30. van der Molen T, Postma DS, Turner MO, Jong BM, Malo JL, Chapman K, et al. Effects of the long acting beta agonist formoterol on asthma control in asthmatic patients using inhaled corticosteroids. The Netherlands and Canadian Formoterol Study Investigators. Thorax 1997; Vol. 52, issue 6:535–9.
31. van der Molen T, Sears MR, de Graaff CS, Postma DS, Meyboom-de Jong B. Quality of life during formoterol treatment: comparison between asthma-specific and generic questionnaires. Canadian and the Dutch Formoterol Investigators. European Respiratory Journal 1998; Vol. 12, issue 1:30–4.
32. Cloosterman SG, Bijl-Hofland ID, van Herwaarden CL, Akkermans RP, van Den Elshout FJ, Folgering HT, et al. A placebo-controlled clinical trial of regular monotherapy with short-acting and long-acting beta2-agonists in allergic asthmatic patients. Chest 2001; Vol. 119, issue 5:1306–15.
33. van Schayck CP, Bijl-Hofland ID, Cloosterman SG, Folgering HT, van der Elshout FJ, Van Weel C. Potential masking effect on dyspnoea perception by short- and longacting beta2-agonists in asthma. European Respiratory Journal 2002; Vol. 19, issue 2:240–5.
34. van Schayck CP, Cloosterman SG, Bijl-Hofland ID, van den Hoogen H, Folgering HT, van Weel C. Is the increase in bronchial responsiveness or FEV1 shortly after cessation of beta2-agonists reflecting a real deterioration of the disease in allergic asthmatic patients? A comparison between short-acting and long-acting beta2-agonists. Respiratory Medicine 2002; Vol. 96, issue 3:155–62.
35. Von Berg A, Papageorgiou Saxoni F, Wille S, Carrillo T, Kattamis C, Helms PJ. Efficacy and tolerability of formoterol turbuhaler in children. International Journal of Clinical Practice 2003; Vol. 57, issue 10:852–6.
36. Friedman B, Sokoi W, Ziehmer B, Orevillo C, Till D. Comparable efficacy and tolerability of formoterol 12 μg or 24 μg twice daily in asthma patients [Abstract]. European Respiratory Journal 2005; Vol. 26, issue Suppl 49:Abstract No. 435.
37. Gunkel H. FDA Clinical Review: Foradil Aerolizer. www.fda.gov/OHRMS/DOCKETS/ac/05/briefing/2005-4148B1˙03˙03-FDA-Clinical-Review.pdf Accessed 16 June 2008.
38. Wolfe J, LaForce C, Ostrom NK, Korenblat P, Orevillo C, Ziehmer B, et al. Formoterol 24 μg is not associated with an increase in serious asthma exacerbations in patients with persistent asthma [Abstract]. Journal of Allergy and Clinical Immunology 2005; Vol. 115, issue Suppl 2:S150.
39. Wolfe J, LaForce C, Ziehmer B, Orevillo C, Till D. No evidence for increase in serious asthma exacerbations with formoterol 24ug twice daily [Abstract]. European Respiratory Journal 2005; Vol. 26, issue Suppl 49:Abstract No. 434.
40. Wolfe J, Laforce C, Friedman B, Sokol W, Till D, Della Cioppa G, et al. Formoterol, 24 microg bid, and serious asthma exacerbations: similar rates compared with formoterol, 12 microg bid, with and without extra doses taken on demand, and placebo. Chest 2006; Vol. 129, issue 1:27–38.
41. Zimmerman B, D’Urzo A, Berube D. Efficacy and safety of formoterol turbuhaler(R) when added to inhaled corticosteroid treatment in children with asthma. Pediatric Pulmonology 2004; Vol. 37, issue 2:122–7.
42. Zimmerman B, D’Urzo A, Berube D. Efficacy and tolerability of formoterol Turbuhaler in 6-11 year old children with asthma, not adequately controlled with inhaled corticosteroids [abstract]. European Respiratory Society Annual Congress 2002 2002:Abstract no: P2734.
43. Zimmerman B, D’Urzo A, Berube D. Efficacy and tolerability of formoterol turbuhaler compared with placebo in children (6-11 years) with asthma poorly controlled with inhaled corticosteroids. American Journal of Respiratory and Critical Care Medicine 2002; Vol. 165, issue Suppl 8: A746.
44. Adler A, Uziel Y, Mei-Zahav M, Horowitz I. Formoterol induces tolerance to the bronchodilating effect of salbutamol following methacholine-provocation test in asthmatic children. Pulmonary Pharmacology and Therapeutics 2006; Vol. 19, issue 4:281–5.
45. Akpinarli A, Tuncer A, Saraclar Y, Sekerel BE, Kalayci O. Effect of formoterol on clinical parameters and lung functions in patients with bronchial asthma: a randomised controlled trial. Archives of Disease in Childhood 1999; Vol. 81, issue 1:45–8.
46. Ankerst J, Persson G, Weibull E. Tolerability of a high dose of budesonide/formoterol in a single inhaler in patients with asthma. Pulmonary Pharmacology and Therapeutics 2003; Vol. 16, issue 3:147–51.
47. Arvidsson P, Larsson S, Lofdahl CG, Melander B, Wahlander L, Svedmyr N. Formoterol, a new long-acting bronchodilator for inhalation. European Respiratory Journal 1989; Vol. 2, issue 4:325–30.
48. Aziz I, McFarlane LC, Lipworth BJ. Concomitant inhaled corticosteroid resensitises cardiac beta2-adrenoceptors in the presence of long-acting beta2-agonist therapy. European Journal of Clinical Pharmacology 1998; Vol. 54, issue 5: 377–81.
49. Bauer K, Sertl K, Kaik B, Kaik G. Effect of solution and suspension type aerosol of formoterol on tremor response and airways in patients with asthma. Journal of Allergy and Clinical Immunology 1995; Vol. 96, issue 4:495–501.
50. Behling B, Matthys H. Comparison of efficacy and safety of formoterol with terbutaline in children with mild to moderate asthma. European Respiratory Society; 1999 Oct 9-13; Madrid, Spain 1999:P369.
51. Boner AL, Spezia E, Piovesan P, Chiocca E, Maiocchi G. Inhaled formoterol in the prevention of exercise-induced bronchoconstriction in asthmatic children. American Journal of Respiratory and Critical Care Medicine 1994; Vol. 149, issue 4 Pt 1:935–9.
52. Bousquet J, Guenole E, Duvauchelle T, Vicaut E, Lefrancois G. A randomized, double-blind, double-dummy, singledose, crossover trial evaluating the efficacy and safety profiles of two dose levels (12 and 24 microg) of formoterol-HFA (pMDI) vs. those of a dose level (24 microg) of formoterol-DPI (Foradil/Aerolizer) and of placebo (pMDI or Aerolizer) in moderate to severe asthmatic patients. Respiration 2005; Vol. 72, issue Suppl 1:13–9.
53. Bousquet J, Huchon G, Leclerc V, Vicaut E, Lefrancois G. A randomized, double-blind, double-dummy, single-dose, efficacy crossover trial comparing formoterol-HFA (pMDI) versus formoterol-DPI (Aerolizer) and placebo (pMDI or Aerolizer) in asthmatic patients. Respiration 2005; Vol. 72, issue Suppl 1:6–12.
54. Brambilla C, Le Gros V, Bourdeix I, Efficacy of Foradil in Asthma French Study G. Formoterol 12 microg BID administered via single-dose dry powder inhaler in adults with asthma suboptimally controlled with salmeterol or ondemand salbutamol: a multicenter, randomized, open-label, parallel-group study. Clinical Therapeutics 2003; Vol. 25, issue 7:2022–36.
55. Bronsky EA, Yegen U, Yeh CM, Larsen LV, Della Cioppa G. Formoterol provides long-lasting protection against exercise-induced bronchospasm. Annals of Allergy, Asthma and Immunology 2002; Vol. 89, issue 4:407–12.
56. Bronsky EA, Grossman J, Henis MJ, Gallo PP, Yegen U, Della Cioppa G, et al. Inspiratory flow rates and volumes with the Aerolizer dry powder inhaler in asthmatic children and adults. Current Medical Research & Opinion 2004; Vol. 20, issue 2:131–7.
57. Brusasco V, Crimi E, Gherson G, Nardelli R, Oldani V, Francucci B, et al. Actions other than smooth muscle relaxation may play a role in the protective effects of formoterol on the allergen-induced late asthmatic reaction. Pulmonary Pharmacology & Therapeutics 2002; Vol. 15, issue 4:399–406.
58. Burgess C, Ayson M, Rajasingham S, Crane J, Della Cioppa G, Till MD. The extrapulmonary effects of increasing doses of formoterol in patients with asthma. European Journal of Clinical Pharmacology 1998; Vol. 54, issue 2:141–7.
59. Cazzola M, Grella E, Matera MG, Mazzarella G, Marsico SA. Onset of action following formoterol Turbuhaler and salbutamol pMDI in reversible chronic airway obstruction. Pulmonary Pharmacology and Therapeutics 2002; Vol. 15, issue 2:97–102.
60. Ceylan E, Mehmet G, Sahin A. Addition of formoterol or montelukast to low-dose budesonide: an efficacy comparison in short- and long-term asthma control. Respiration 2004; Vol. 71, issue 6:594–601.
61. Chetta A, Del Donno M, Maiocchi G, Pisi G, Moretti D, Olivieri D. Prolonged bronchodilating effect of formoterol versus procaterol in bronchial asthma. Annals of Allergy 1993; Vol. 70, issue 2:171–4.
62. Cheung D, van Klink HCJ, Aalbers R. Improved lung function and symptom control with formoterol on demand in asthma. European Respiratory Journal 2006; Vol. 27, issue 3:504–10.
63. Chuchalin AG, Ovcharenko SI, Goriachkina LA, Sidorenko IV, Tsoi AN, Epoch Study G. The safety and efficacy of formoterol OxisR TurbuhalerR plus budesonide PulmicortR Turbuhaler in mild to moderate asthma: A comparison with budesonide Turbuhaler alone and current noncorticosteroid therapy in Russia. International Journal of Clinical Practice 2002; Vol. 56, issue 1:15–20.
64. Chuchalin A, Kasl M, Bengtsson T, Nihlen U, Rosenborg J. Formoterol used as needed in patients with intermittent or mild persistent asthma. Respiratory Medicine 2005; Vol. 99, issue 4:461–70.
65. Chuchalin AG, Manjra AI, Rozinova NN, Skopkova O, Cioppa GD, Till D, et al. Formoterol delivered via a new multi-dose dry powder inhaler (Certihaler) is as effective and well tolerated as the formoterol dry powder inhaler (Aerolizer) in children with persistent asthma. Journal of Aerosol Medicine 2005; Vol. 18, issue 1:63–73.
66. Chung KF. Eformoterol and bronchial hyperresponsiveness in mild asthma. British Journal of Clinical Practice. Supplement 1995, issue 81:14–5.
67. Dahl R, Creemers JP, Van Noord J, Sips A, Della Cioppae G, Thomson M, et al. Comparable efficacy and tolerability of formoterol (Foradil) administered via a novel multi-dose dry powder inhaler (Certihaler) or the Aerolizer dry powder inhaler in patients with persistent asthma. Respiration 2004; Vol. 71, issue 2:126–33.
68. Daugbjerg P, Nielsen KG, Skov M, Bisgaard H. Duration of action of formoterol and salbutamol dry-powder inhalation in prevention of exercise-induced asthma in children. Acta Paediatrica 1996; Vol. 85, issue 6:684–7.
69. Dey. Study in patients with asthma. Clinicaltrials.gov 2005.
70. Dietrich H, Nguyen TD, Buermann U, Petzold U, Munzel U, Maus J. Pharmacodynamic (PD) pharmacokinetic (PK) and safety profile of formoterol delivered via two different dry different dry powder inhalers (DPIs) [Abstract]. European Respiratory Journal 2006; Vol. 28, issue Suppl 50:614s [E3606].
71. Dubakiene R, Nargela R, Sakalauskas R, Vahteristo M, Silvasti M, Lahelma S. Clinically equivalent bronchodilatation achieved with formoterol delivered via Easyhaler and Aerolizer. Respiration 2006; Vol. 73, issue 4: 441–8.
72. Dusser D, Vicaut E, Lefrancois G. Double-blind, doubledummy, multinational, multicenter, parallel-group design clinical trial of clinical non-inferiority of formoterol 12 microg/unit dose in a b.i.d. regimen administered via an HFA-propellant-pMDI or a dry powder inhaler in a 12-week treatment period of moderate to severe stable persistent asthma in adult patients. Respiration 2005; Vol. 72, issue Suppl 1:20–7.
73. Ericsson K, Bantje TA, Huber RM, Borg S, Bateman ED. Cost-effectiveness analysis of budesonide/formoterol compared with fluticasone in moderate-persistent asthma. Respiratory Medicine 2006; Vol. 100, issue 4:586–94.
74. Eryonucu B, Uzun K, Guler N, Tuncer M, Sezgi C. Comparison of the short-term effects of salmeterol and formoterol on heart rate variability in adult asthmatic patients. Chest 2005; Vol. 128, issue 3:1136–9.
75. Ferrari M, Balestreri F, Baratieri S, Biasin C, Oldani V, Lo Cascio V. Evidence of the rapid protective effect of formoterol dry-powder inhalation against exercise-induced bronchospasm in athletes with asthma. Respiration 2000; Vol. 67, issue 5:510–3.
76. Fitoussi S, Dobson C, Ayre G, Langholff W. Safety and tolerability profile of high dose formoterol (Aerolizer®) and salbutamol (MDI) given for three days in patients with mild persistent asthma. Chest 2002:P117.
77. Gessner C, Stenglein S, Brautigam M, Muller A, Schauer J. Miflonide/Foradil via Aerolizer compared with other antiinflammatory and anti-obstructive therapeutic regimens [German]. Pneumologie 2003; Vol. 57, issue 3:137–43.
78. Graff-Lonnevig V, Browaldh L. Twelve hours’ bronchodilating effect of inhaled formoterol in children with asthma: a double-blind cross-over study versus salbutamol. Clinical and Experimental Allergy 1990; Vol. 20, issue 4:429–32.
79. Green RH, Brightling CE, McKenna S, Hargadon B, Neale N, Parker D, et al. Comparison of asthma treatment given in addition to inhaled corticosteroids on airway inflammation and responsiveness. European Respiratory Journal 2006; Vol. 27, issue 6:1144–51.
80. Happonen P, Harkonen M, Vaheri R, Rytila P. Longterm safety of inhaled formoterol in adult asthma patients [Abstract]. European Respiratory Society Annual Congress, Vienna, Austria, September 12-16 2009:[P1964].
81. Hedenstrom H, Wegener T, Boman G, Wahlander L, Melander B. Effect of inhaled formoterol versus terbutaline on respiratory function in moderate bronchial asthma. Allergy 1992; Vol. 47, issue 2 Pt 2:158–63.
82. Hermansen MN, Nielsen KG, Buchvald F, Jespersen JJ, Bengtsson T, Bisgaard H. Acute relief of exercise-induced bronchoconstriction by inhaled formoterol in children with persistent asthma. Chest 2006; Vol. 129, issue 5:1203–9.
83. Houghton CM, Langley SJ, Singh SD, Holden J, Monici Preti AP, Acerbi D, et al. Comparison of bronchoprotective and bronchodilator effects of a single dose of formoterol delivered by hydrofluoroalkane and chlorofluorocarbon aerosols and dry powder in a double blind, placebocontrolled, crossover study. British Journal of Clinical Pharmacology 2004; Vol. 58, issue 4:359–66.
84. Ind PW, Villasante C, Shiner RJ, Pietinalho A, Boszormenyi NG, Soliman S, et al. Safety of formoterol by Turbuhaler as reliever medication compared with terbutaline in moderate asthma. European Respiratory Journal 2002; Vol. 20, issue 4:859–66.
85. Jain A, Raghuram J. Randomized controlled study of the safety and efficacy of PRN formoterol compared to PRN albuterol for the management of asthma [Abstract]. American Thoracic Society 100th International Conference, May 21-26, 2004, Orlando 2004:B36 Poster G17.
86. Jenkins CR, Thien FCK, Wheatley JR, Reddel HK. Traditional and patient-centred outcomes with three classes of asthma medication. European Respiratory Journal 2005; Vol. 26, issue 1:36–44.
87. Kamenov A, Kamenov S, Kamenov B. The efficacy and safety formoterol-HFA pMDI in school children with persistent asthma [Abstract]. European Respiratory Journal 2007; Vol. 30, issue Suppl 51:460s [E2712].
88. Kesten S, Chapman KR, Broder I, Cartier A, Hyland RH, Knight A, et al. Sustained improvement in asthma with long-term use of formoterol fumarate. Annals of Allergy 1992; Vol. 69, issue 5:415–20.
89. Kohler D, Schmidt F, Wiese C, Dellweg D, Haidl P. Safety concerns regarding the use of the formoterol Turbohaler® for acute asthma attacks [abstract]. American Thoracic Society 99th International Conference 2003:B036 Poster H74.
90. Kruse M, Rosenkranz B, Dobson C, Ayre G, Horowitz A. Safety and tolerability of high-dose formoterol (Aerolizer) and salbutamol (pMDI) in patients with mild/ moderate, persistent asthma. Pulmonary Pharmacology and Therapeutics 2005; Vol. 18, issue 3:229–34.
91. Lebecque P, Vliers S, De Saint-Moulin T, Godding V. The effect of a single dose of formoterol using an aerosol inhaler in asthmatic children. A randomized, controlled, doubleblind study. Revue des Maladies Respiratoires 1994; Vol. 11, issue 1:47–50.
92. Lebecque P, Vliers S, De SMT, Godding V. Response to a single dose of inhaled formoterol in asthmatic children: a double-blind randomized controlled study. Revue des Maladies Respiratoires 1994; Vol. 11, issue 1:47–50.
93. Lee-Wong M, Chou V, Ogawa Y. Formoterol fumarate inhalation powder vs albuterol nebulizer for the treatment of asthma in the acute care setting. Annals of Allergy, Asthma, and Immunology 2008; Vol. 100, issue 2:146–52.
94. Lemaigre V, Van den Bergh O, Smets A, De Peuter S, Verleden GM. Effects of long-acting bronchodilators and placebo on histamine-induced asthma symptoms and mild bronchus obstruction. Respiratory Medicine 2006; Vol. 100, issue 2:348–53.
95. Lotvall J, Persson G, Larsson P, Mardell C, Rosenborg J. Tolerability of inhaled high doses of formoterol and salbutamol in asthmatic patients maintained on twice daily formoterol 12 (9μg) delivered [abstract]. European Respiratory Journal. Supplement 1997; Vol. 10 Suppl 25: 103S.
96. Lotvall J, Palmqvist M, Ankerst J, Persson G, Rosenborg J, Bengtsson T, et al. The effect of formoterol over 24 h in patients with asthma: the role of enantiomers. Pulmonary Pharmacology and Therapeutics 2005; Vol. 18, issue 2: 109–13.
97. Lotvall J, Ankerst J. Long duration of airway but not systemic effects of inhaled formoterol in asthmatic patients. Respiratory Medicine 2008; Vol. 102, issue 3:449–56.
98. Lyseng-Williamson KA, Plosker GL. Inhaled salmeterol/fluticasone propionate combination: a pharmacoeconomic review of its use in the management of asthma. Pharmacoeconomics 2003; Vol. 21, issue 13:951–89.
99. Maesen FP, Costongs R, Smeets SJ, Zweers PG, Goedhart DM. Formoterol as dry powder inhalation. A dose finding study in comparison with formoterol metered dose inhaler and placebo. Chest 1992; Vol. 101, issue 5:1376–81.
100. Maesen FP, Nakratzas G, Bantje TA, Prins J, Zweers PG. Formoterol suspension aerosol. Comparison with formoterol solution aerosol for 12 weeks in asthmatic patients. Chest 1992; Vol. 102, issue 5:1544–9.
101. Malo JL, Cartier A, Trudeau C, Ghezzo H, Gontovnick L. Formoterol, a new inhaled beta-2 adrenergic agonist, has a longer blocking effect than albuterol on hyperventilationinduced bronchoconstriction. American Review of Respiratory Disease 1990; Vol. 142, issue 5:1147–52.
102. Malolepszy J, Boszormenyi Nagy G, Selroos O, Larsso P, Brander R. Safety of formoterol Turbuhaler at cumulative dose of 90 microg in patients with acute bronchial obstruction. European Respiratory Journal 2001; Vol. 18, issue 6:928–34.
103. Malolepszy J. Efficacy and tolerability of oral theophylline slow-release versus inhalative formoterol in moderate asthma poorly controlled on low-dose steroids. Atemwegsund Lungenkrankheiten 2002; Vol. 28, issue 2:78–87.
104. Mann M, Chowdhury B, Sullivan E, Nicklas R, Anthracite R, Meyer RJ. Serious asthma exacerbations in asthmatics treated with high-dose formoterol. Chest 2003; Vol. 124, issue 1:70–4.
105. Marzo A, Monti NC, Tettamanti RA, Crivelli F, Dal Bo L, Mazzucchelli P, et al. Bioequivalence of inhaled formoterol fumarate assessed from pharmacodynamic, safety and urinary pharmacokinetic data. Arzneimittel-Forschung 2000; Vol. 50, issue 6:559–63.
106. Matthys H, Behling B, Behling E. Comparison of formoterol (12 and 6 mug b.i.d) vs terbutaline (0.5 mg b.i.d) with equal doses of inhaled budesonide (0.2 mg bid) in 246 children with mild to moderate asthma. Atemwegsund Lungenkrankheiten 2004; Vol. 30, issue 5:251–6.
107. Midgren B, Melander B, Persson G. Formoterol, a new long-acting beta 2 agonist, inhaled twice daily, in stable asthmatic subjects. Chest 1992; Vol. 101, issue 4:1019–22.
108. Molimard M, Guenole E, Duvauchelle T, Vicaut E, Lefrancois G. A randomized, double-blind, double-dummy, safety crossover trial comparing cumulative doses up to 96 microg of formoterol delivered via an HFA-134a-propelled pMDI vs. same cumulative doses of formoterol DPI and placebo in asthmatic patients. Respiration 2005; Vol. 72, issue Suppl 1:28–34.
109. Najafizadeh K, Pour HS, Ghadyanee M, Shiehmorteza M, Jamali M, Majdzadeh S. A randomized, double-blind, placebo-controlled study to evaluate the role of formoterol in the management of acute asthma. Emergency Medicine Journal 2007; Vol. 24, issue 5:317–21.
110. Nandeuil A, Kottakis I, Raptis H, Roslan H, Ivanov Y, Woodcock A. Safety and tolerability of the novel very long acting B2 agonist carmoterol given as a 2μg qd dose 8 days comparison with formoterol and placebo in patients with persistent asthma [Abstract]. European Respiratory Journal 2006; Vol. 28, issue Suppl 50:665s [P3859].
111. Newnham DM, McDevitt DG, Lipworth BJ. Bronchodilator subsensitivity after chronic dosing with eformoterol in patients with asthma. American Journal of Medicine 1994; Vol. 97, issue 1:29–37.
112. Newnham DM, Grove A, McDevitt DG, Lipworth BJ. Subsensitivity of bronchodilator and systemic beta 2 adrenoceptor responses after regular twice daily treatment with eformoterol dry powder in asthmatic patients. Thorax 1995; Vol. 50, issue 5:497–504.
113. Novartis. A 12-month multicenter, randomized, doubleblind, double-dummy trial to examine the long-term tolerability of fomoterol 10μg via the multiple dose dry powder inhaler (MDDPI), both as twice daily maintenance therapy and as on-demand use in addition to maintenance in patients with persistent asthma. http://pharma.us.novartis.com/2005.
114. Otto-Knapp R, Conrad F, Hosch S, Metzenauer P, Maus J, Noga O, et al. Efficacy and safety of formoterol delivered through the Novolizer, a novel dry powder inhaler (DPI) compared with a standard DPI in patients with moderate to severe asthma. Pulmonary Pharmacology and Therapeutics 2008; Vol. 21, issue 1:47–53.
115. Patessio A, Podda A, Carone M, Trombetta N, Donner CF. Protective effect and duration of action of formoterol aerosol on exercise-induced asthma. European Respiratory Journal 1991; Vol. 4, issue 3:296–300.
116. Pauwels RA, Sears MR, Campbell M, Villasante C, Huang S, Lindh A, et al. Formoterol as relief medication in asthma: a worldwide safety and effectiveness trial. European Respiratory Journal 2003; Vol. 22, issue 5:787–94.
117. Pearlman DS, Kottakis J, Till D, Della Cioppa G. Formoterol delivered via a dry powder inhaler (Aerolizer): esults from long-term clinical trials in children. Current Medical Research and Opinion 2002; Vol. 18, issue 8: 445–55.
118. Pohunek P, Matulka M, Rybnicek O, Kopriva F, Honomichlova H, Svobodova T. Dose-related efficacy and safety of formoterol (Oxis) Turbuhaler compared with salmeterol Diskhaler in children with asthma. Pediatric Allergy & Immunology 2004; Vol. 15, issue 1:32–9.
119. Price D, Dutchman D, Mawson A, Bodalia B, Duggan S, Todd P. Early asthma control and maintenance with eformoterol following reduction of inhaled corticosteroid dose. Thorax. 2002/08/30 2002; Vol. 57, issue 9:791–8. [0040–6376: (Print)]
120. Price J, Radner F, Hultquist C, Lindberg B. Safety of formoterol in children and adolescents: experience from asthma clinical trials [Abstract]. European Respiratory Society Annual Congress, Berlin, Germany, October 4-8 2008:[E3053].
121. Randell J, Saarinen A, Walamies M, Vahteristo M, Silvasti M, Lahelma S. Safety of formoterol after cumulative dosing via Easyhaler and Aerolizer. Respiratory Medicine 2005; Vol. 99, issue 12:1485–93.
122. Richter K, Hartmann U, Metzenauer P, Magnussen H. Randomised trial comparing as-needed versus regular treatment with formoterol in patients with persistent asthma. Respiratory Medicine 2007; Vol. 101, issue 3: 467–75.
123. Rico-Mendez FG, Ochoa G, Rocio Chapela M, Diaz M, Cohen V, Ibarra J, et al. Dry powdered formoterol, twice a day versus aerosolized salbutamol, four times a day, in patients with stable asthma. Revista Alergia Mexico 1999; Vol. 46, issue 5:130–5.
124. Ringdal N, Derom E, Wahlin-Boll E, Pauwels R. Onset and duration of action of single doses of formoterol inhaled via Turbuhaler. Respiratory Medicine 1998; Vol. 92, issue 8: 1017–21.
125. Rosenborg J, Bengtsson T, Larsson P, Blomgren A, Persson G, Lötvall J. Relative systemic dose potency and tolerability of inhaled formoterol and salbutamol in healthy subjects and asthmatics. European Journal of Clinical Pharmacology 2000; Vol. 56, issue 5:363–70.
126. Rosenborg J, Bengtsson T, Larsson P, Blomgren A, Persson G, Lötvall J. Relative systemic dose potency and tolerability of inhaled formoterol and salbutamol in healthy subjects and asthmatics. European Journal of Clinical Pharmacology 2002; Vol. 58, issue 4:S53–60.
127. Rosenborg J, Larsson P, Rott Z, Bocskei C, Poczi M, Juhasz G. Assessment of a relative therapeutic index between inhaled formoterol and salbutamol in asthma patients. European Journal of Clinical Pharmacology 2002; Vol. 58, issue 4:S61–7.
128. Rubinfeld AR, Scicchitano R, Hunt A, Thompson PJ, Van Nooten A, Selroos O. Formoterol Turbuhaler as reliever medication in patients with acute asthma. European Respiratory Journal. 2006; Vol. 27, issue 4:735–41.
129. Schlimmer P. Single-dose comparison of formoterol (Oxis) Turbuhaler 6 mug and formoterol Aerolizer 12 mug in moderate to severe asthma: a randomised, crossover study. Pulmonary Pharmacology and Therapeutics 2002; Vol. 15, issue 4:369–74.
130. Sprogoe Jakobsen U, Viktrup L, Davidsen O, Viskum K. Bronchial asthma treated with long-acting beta 2 agonist. Comparison between formoterol 12 mu/g inhaled twice daily and salbutamol 200. Ugeskrift for Laeger 1992; Vol. 154, issue 47:3325–8.
131. Stahl E, Postma DS, Svensson K, Tattersfield AE, Eivindson A, Schreurs A, et al. Formoterol used as needed improves health-related quality of life in asthmatic patients uncontrolled with inhaled corticosteroids. Respiratory Medicine 2003; Vol. 97, issue 9:1061–6.
132. Stelmach I, Grzelewski T, Majak P, Jerzynska J, Stelmach W, Kuna P. Effect of different antiasthmatic treatments on exercise-induced bronchoconstriction in children with asthma. Journal of Allergy & Clinical Immunology 2008; Vol. 121, issue 2:383–9.
133. Tattersfield AE, Postma DS, Barnes PJ, Svensson K, Bauer CA, O’Byrne PM, et al. Exacerbations of asthma: a descriptive study of 425 severe exacerbations. The FACET International Study Group. American Journal of Respiratory and Critical Care Medicine 1999; Vol. 160, issue 2:594–9.
134. Tattersfield AE, Lofdahl CG, Postma DS, Eivindson A, Schreurs AG, Rasidakis A, et al. Comparison of formoterol and terbutaline for as-needed treatment of asthma: a randomised trial. Lancet 2001; Vol. 357, issue 9252: 257–61.
135. Totterman KJ, Huhti L, Sutinen E, Backman R, Pietinalho A, Falck M, et al. Tolerability to high doses of formoterol and terbutaline via Turbuhaler for 3 days in stable asthmatic patients. European Respiratory Journal 1998; Vol. 12, issue 3:573–9.
136. van den Berg BT, Smeets JJ, van Boxtel CJ, Maesen FP. Evaluation of different doses of formoterol from a newly developed powder inhalation device in asthmatic patients. Fundamental & Clinical Pharmacology 1995; Vol. 9, issue 6:593–603.
137. van der Woude HJ, Postma DS, Politiek MJ, Winter TH, Aalbers R. Relief of dyspnoea by beta2-agonists after methacholine-induced bronchoconstriction. Respiratory Medicine 2004; Vol. 98, issue 9:816–20.
138. van Veen A, Weller FR, Wierenga EA, Jansen HM, Jonkers RE. A comparison of salmeterol and formoterol in attenuating airway responses to short-acting beta2-agonists. Pulmonary Pharmacology and Therapeutics 2003; Vol. 16, issue 3:153–61.
139. Verini M, Verrotti A, Greco R, Chiarelli F. Comparison of the bronchodilator effect of inhaled short- and longacting beta2-agonists in children with bronchial asthma. A randomised trial. Clinical Drug Investigation 1998; Vol. 16, issue 1:19–24.
140. ® as needed in asthmatic children on anti-inflammatory medication [abstract]. American Journal of Respiratory and Critical Care Medicine 2002; Vol. 165, issue Suppl 8:A746.
141. Villa J, Kuna P, Egner J, Brander R. Safety of formoterol reliever therapy compared with terbutaline in asthmatic children taking anti-inflammatory therapy [abstract]. European Respiratory Society Annual Congress 2002 2002: Abstract no: P2739.
142. Vilsvik J, Ankerst J, Palmqvist M, Persson G, Schaanning J, Schwabe G, et al. Protection against cold air and exerciseinduced bronchoconstriction while on regular treatment with Oxis. Respiratory Medicine 2001; Vol. 95, issue 6: 484–90.
143. Wallin A, Sandstrom T, Soderberg M, Howarth P, Lundback B, Della-Cioppa G, et al. The effects of regular inhaled formoterol, budesonide, and placebo on mucosal inflammation and clinical indices in mild asthma. American Journal of Respiratory and Critical Care Medicine 1999; Vol. 159, issue 1:79–86.
144. Wegener T, Hedenstrom H, Melander B. Rapid onset of action of inhaled formoterol in asthmatic patients. Chest 1992; Vol. 102, issue 2:535–8.
145. Wong BJ, Dolovich J, Ramsdale EH, O’Byrne P, Gontovnick L, Denburg JA, et al. Formoterol compared with beclomethasone and placebo on allergen-induced asthmatic responses. American Review of Respiratory Disease 1992; Vol. 146, issue 5 Pt 1:1156–60.
146. Yasuo K, Takao I S, Mitsuru W, Terumi T, Shigenori N, Eisei N, et al. Evaluation of therapeutic effects of formoterol, a new beta-receptor stimulating bronchodilator, on bronchial asthma - a joint double-blind repeated-dose study at 37 institutions. Rinsho Hyoka (Clinical Evaluation) 1984; Vol. 12, issue 3:697–727.
147. Yasuo K, Terumi T, Mitsuru I, Takao S, Shigenori N, Eisei N, et al. Evaluation of therapeutic effects of formoterol, a beta-receptor stimulating bronchodilator, on bronchial asthma - a joint double-blind single-dose study at 37 institutions Part 2. Rinsho Hyoka (Clinical Evaluation) 1984; Vol. 12, issue 3:671–95.
148. Yasuo K, Terumi I T, Kazuhiko TO, Takao S, Shigenori N, Eisei N, et al. Evaluation of therapeutic effects of formoterol, a beta-receptor stimulating bronchodilator, on bronchial asthma - a joint double-blind single-dose study at 30 institutions Part 1. Rinsho Hyoka (Clinical Evaluation) 1984; Vol. 12, issue 3:647–70.
149. Yates DH, Sussman HS, Shaw MJ, Barnes PJ, Chung KF. Regular formoterol treatment in mild asthma: effect on bronchial responsiveness during and after treatment. American Journal of Respiratory and Critical Care Medicine 1995; Vol. 152, issue 4 I:1170–4.
150. Yurdakul AS, Calisir HC, Tunctan B, Ogretensoy M. Comparison of second controller medications in addition to inhaled corticosteroid in patients with moderate asthma. Respiratory Medicine 2002; Vol. 96, issue 5:322–9.
151. Altman DG, Bland JM. Statistics notes: interaction revisited: the difference between two estimates. BMJ 2003; 326(7382):219.
152. Anderson GP. Current issues with beta(2)-adrenoceptor agonists - pharmacology and molecular and cellular mechanisms. Clinical Reviews in Allergy and Immunology 2006; Vol. 31, issue 2–3:119–30.
153. Arnold JMO, O’Connor PC, Riddell JG, Harron DWG, Shanks RG, McDevitt DG. Effects of the beta-2-adrenoceptor antagonist ici-118,551 on exercise tachycardia and isoprenaline-induced beta-adrenoceptor responses in man. British Journal of Clinical Pharmacology 1985; Vol. 19, issue 5:619–30.
154. Barnes PJ. Beta-adrenoceptors on smooth-muscle, nerves and inflammatory cells. Life Sciences 1993; Vol. 52, issue 26:2101–9.
155. Barnes PJ. Beta-adrenergic receptors and their regulation. American Journal of Respiratory and Critical Care Medicine 1995; Vol. 152, issue 3:838–60.
156. Bennett JA, Smyth ET, Pavord ID, Wilding PJ, Tattersfield AE. Systemic effects of salbutamol and salmeterol in patients with asthma. Thorax 1994; Vol. 49, issue 8:771–4.
157. Benson RL, Perlman F. Clinical effects of epinephrine by inhalation - a survey. Journal of Allergy 1948; Vol. 19, issue 2:129–40.
158. Bergman J, Persson H, Wetterlin K. Two new groups of selective stimulants of adrenergic beta-receptors. Experientia 1969; Vol. 25, issue 9:899–901.
159. Bijl-Hofland ID, Cloosterman SG, Folgering HT, van den Elshout FJ, van Weel C, van Schayck CP. Inhaled corticosteroids, combined with long-acting beta(2)-agonists, improve the perception of bronchoconstriction in asthma. American Journal of Respiratory and Critical Care Medicine 2001; Vol. 164, issue 5:764–9.
160. Blauw GJ, Westendorp RGJ. Asthma deaths in New Zealand - whodunnit. The Lancet 1995;345:2–3.
161. Boushey HA, Holtzman MJ, Sheller JR, Nadel JA. Bronchial hyperreactivity. American Review of Respiratory Disease 1980; Vol. 121, issue 2:389–413. [(Print)]
162. Bousquet J, Chanez P, Lacoste JY, Barneon G, Ghavanian N, Enander I, et al. Eosinophilic inflammation in asthma. New England Journal of Medicine 1990; Vol. 323, issue 15:1033–9.
163. Bousquet J, Jeffery PK, Busse WW, Johnson M, Vignola AM. Asthma. From bronchoconstriction to airways inflammation and remodeling. American Journal Respiratory Critical Care Medicine 2000; Vol. 161, issue 5: 1720–45.
164. Bradburn MJ, Deeks JJ, Berlin JA, Russell Localio A. Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events. Statistics in Medicine 2007; Vol. 26, issue 1:53–77. [0277–6715: (Print)]
165. Brewster CEP, Howarth PH, Djukanovic R, Wilson J, Holgate ST, Roche WR. Myofibroblasts and subepithelial fibrosis in bronchial-asthma. American Journal of Respiratory Cell and Molecular Biology 1990; Vol. 3, issue 5:507–11.
166. Brown MJ, Brown DC, Murphy MB. Hypokalemia from beta-2-receptor stimulation by circulating epinephrine. New England Journal of Medicine 1983; Vol. 309, issue 23:1414–9.
167. Brusasco V, Crimi E, Pellegrino R. Airway hyperresponsiveness in asthma: not just a matter of airway inflammation. Thorax 1998; Vol. 53, issue 11:992–8.
168. Burgess CD, Windom HH, Pearce N, Marshall S, Beasley R, Siebers RWL, et al. Lack of evidence for beta-2 receptor selectivity - a study of metaproterenol, fenoterol, isoproterenol, and epinephrine in patients with asthma. American Review of Respiratory Disease 1991; Vol. 143, issue 2:444–6.
169. Burggraaf J, Westendorp RGJ, in’t Veen J, Schoemaker RC, Sterk PJ, Cohen AF, et al. Cardiovascular side effects of inhaled salbutamol in hypoxic asthmatic patients. Thorax 2001; Vol. 56, issue 7:567–9.
170. Carroll N, Elliot J, Morton A, James A. The structure of large and small airways in nonfatal and fatal asthma. American Review of Respiratory Disease 1993; Vol. 147, issue 2:405–10.
171. Cates CJ, Cates MJ. Regular treatment with salmeterol for chronic asthma: serious adverse events. Cochrane Database of Systematic Reviews 2008, Issue 3. [DOI: 10.1002/14651858.CD006363.pub2]
172. Cates CJ, Lasserson TJ. Regular treatment with formoterol versus regular treatment with salmeterol for chronic asthma: serious adverse events. Cochrane Database of Systematic Reviews 2009, Issue 4. [DOI: 10.1002/14651858.CD007695.pub2]
173. Cates CJ, Lasserson TJ, Jaeschke R. Regular treatment with formoterol and inhaled steroids for chronic asthma: serious adverse events. Cochrane Database of Systematic Reviews 2009, Issue 2. [DOI: 10.1002/14651858.CD006924.pub2]
174. Cates CJ, Lasserson TJ. Regular treatment with formoterol and an inhaled corticosteroid versus regular treatment with salmeterol and an inhaled corticosteroid for chronic asthma: serious adverse events. Cochrane Database of Systematic Reviews 2011, Issue 12. [DOI: 10.1002/14651858.CD007694.pub2]
175. Cockcroft DW, McParland CP, Britto SA, Swystun VA, Rutherford BC. Regular inhaled salbutamol and airway responsiveness to allergen. Lancet 1993; Vol. 342, issue 8875:833–7.
176. Cockcroft D. Airway hyperresponsiveness as a determinant of the early asthmatic response to inhaled allergen. Journal of Asthma 2006; Vol. 43, issue 3:175–8.
177. Collins JM, McDevitt DG, Shanks RG, Swanton JG. Cardio-toxicity of isoprenaline during hypoxia. British Journal of Pharmacology 1969; Vol. 36, issue 1:35–45.
178. Crane J, Pearce N, Flatt A, Burgess C, Jackson R, Kwong T, et al. Prescribed fenoterol and death from asthma in New Zealand, 1981-83 - case-control study. Lancet 1989; Vol. 1, issue 8644:917–22.
179. Cullum VA, Farmer JB, Jack D, Levy GP. Salbutamol - a new selective beta-adrenoceptive receptor stimulant. British Journal of Pharmacology 1969; Vol. 35, issue 1:141–51.
180. Ducharme FM, Lasserson TJ, Cates CJ. Addition to inhaled corticosteroids of long-acting beta2-agonists versus anti-leukotrienes for chronic asthma. Cochrane Database of Systematic Reviews 2011, Issue 8. [DOI: 10.1002/14651858.CD003137]
181. Dunnill MS. The pathology of asthma, with special reference to changes in the bronchial mucosa. Journal of Clinical Pathology 1960; Vol. 13, issue 1:27–33.
182. Ebina M, Takahashi T, Chiba T, Motomiya M. Cellular hypertrophy and hyperplasia of airway smooth muscles underlying bronchial-asthma - a 3-d morphometric study. American Review of Respiratory Disease 1993; Vol. 148, issue 3:720–6.
183. Gay LN, Long JW. Clinical evaluation of isopropylepinephrine in management of bronchial asthma. JAMA 1949; Vol. 139, issue 7:452–7.
184. Grainger J, Woodman K, Pearce N, Crane J, Burgess C, Keane A, et al. Prescribed fenoterol and death from asthma in New Zealand, 1981-7 - a further case-control study. Thorax 1991; Vol. 46, issue 2:105–11.
185. Greenstone IR, Ni Chroinin M, Masse V, Danish A, Magdalinos H, Zhang X, et al. Combination of inhaled long-acting beta2-agonists and inhaled steroids versus higher dose of inhaled steroids in children and adults with persistent asthma. Cochrane Database of Systematic Reviews 2005, Issue 4. [DOI: 10.1002/14651858.CD005533]
186. Guhan AR, Cooper S, Oborne J, Lewis S, Bennett J, Tattersfield AE. Systemic effects of formoterol and salmeterol: a dose-response comparison in healthy subjects. Thorax 2000; Vol. 55, issue 8:650–6.
187. Haley KJ, Drazen JM. Inflammation and airway function in asthma - what you see is not necessarily what you get. American Journal of Respiratory and Critical Care Medicine 1998; Vol. 157, issue 1:1–3.
188. Hall JA, Petch MC, Brown MJ. Intracoronary injections of salbutamol demonstrate the presence of functional beta-2-adrenoceptors in the human-heart. Circulation Research 1989; Vol. 65, issue 3:546–53.
189. Hanania NA, Sharfkhaneh A, Barber R, Dickey BF. Betaagonist intrinsic efficacy - measurement and clinical significance. American Journal of Respiratory and Critical Care Medicine 2002; Vol. 165, issue 10:1353–8.
190. Hanania NA, Moore RH, Zimmerman JL, Miller CT, Bag R, Sharafkhaneh A, et al. The role of intrinsic efficacy in determining response to beta(2)-agonist in acute severe asthma. Respiratory Medicine 2007; Vol. 101, issue 5: 1007–14.
191. Hancox RJ, Aldridge RE, Cowan JO, Flannery EM, Herbison GP, McLachlan CR, et al. Tolerance to betaagonists during acute bronchoconstriction. European Respiratory Journal 1999; Vol. 14, issue 2:283–7.
192. Hancox RJ. Interactions between corticosteroids and beta2- agonists. Clinical Reviews in Allergy & Immunology 2006; Vol. 31, issue 2–3:231–46. [(Print)]
193. Haney S, Hancox RJ. Recovery from bronchoconstriction and bronchodilator tolerance. Clinical Reviews in Allergy and Immunology 2006; Vol. 31, issue 2–3:181–96.
194. Harvey JE, Tattersfield AE. Airway response to salbutamol - effect of regular salbutamol inhalations in normal, atopic, and asthmatic subjects. Thorax 1982; Vol. 37, issue 4: 280–7.
195. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 [updated February 2008] Available from www.cochrane-handbook.org. The Cochrane Collaboration, 2008.
196. Expert Working Group (Efficacy) of the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). Clinical safety data management: definitions and standards for expedited reporting. http://www.fda.gov/cder/guidance/iche2a.pdf 1995.
197. Expert working group (efficacy) of the international conference on harmonization of technical requirements for registration of pharmaceuticals for human use. FDA Center for Drug Evaluation and Research. Guideline for Industry Structure and Content of Clinical Study Reports. http://www.fda.gov/cder/guidance/iche3.pdf 25 August 2007.
198. Jones SL, Cowan JO, Flannery EM, Hancox RJ, Herbison GP, Taylor DR. Reversing acute bronchoconstriction in asthma: the effect of bronchodilator tolerance after treatment with formoterol. European Respiratory Journal 2001; Vol. 17, issue 3:368–73.
199. Kemp JP, Bierman CW, Cocchetto DM. Dose-response study of inhaled salmeterol in asthmatic-patients with 24-hour spirometry and Holter monitoring. Annals of Allergy 1993; Vol. 70, issue 4:316–22.
200. Konzett H. Neue broncholytisch hochwirksame Körper der Adrenalinreihe. Naunyn-Schmiedeberg’s Archives of Pharmacology 1940; Vol. 197:27–40.
201. Kuyper LM, Pare PD, Hogg JC, Lambert RK, Ionescu D, Woods R, et al. Characterization of airway plugging in fatal asthma. American Journal of Medicine 2003; Vol. 115, issue 1:6–11. [(Print)]
202. Lee DKC, Jackson CM, Currie GP, Cockburn WJ, Lipworth BJ. Comparison of combination inhalers vs inhaled corticosteroids alone in moderate persistent asthma. British Journal of Clinical Pharmacology 2003; Vol. 56, issue 5:494–500.
203. Lipworth BJ, Struthers AD, McDevitt DG. Tachyphylaxis to systemic but not to airway responses during prolonged therapy with high-dose inhaled salbutamol in asthmatics. American Review of Respiratory Disease 1989; Vol. 140, issue 3:586–92.
204. Lipworth BJ, McDevitt DG. Inhaled beta-2-adrenoceptor agonists in asthma - help or hindrance. British Journal of Clinical Pharmacology 1992; Vol. 33, issue 2:129–38.
205. Lipworth BJ. Airway subsensitivity with long-acting beta 2-agonists: is there cause for concern?. Drug Safety 1997;16 (5):295–308.
206. Lipworth BJ, Aziz I. Bronchodilator response to albuterol after regular formoterol and effects of acute corticosteroid administration. Chest 2000; Vol. 117, issue 1:156–62.
207. McDevitt DG, Shanks RG, Swanton JG. Further observations on cardiotoxicity of isoprenaline during hypoxia. British Journal of Pharmacology 1974; Vol. 50, issue 3:335–44.
208. McIvor RA, Pizzichini E, Turner MO, Hussack P, Hargreave FE, Sears MR. Potential masking effects of salmeterol on airway inflammation in asthma. American Journal of Respiratory and Critical Care Medicine 1998; Vol. 158, issue 3:924–30.
209. McMahon, Ann W, Levenson, Mark S, McEvoy, Bradley W, et al. Age and Risks of FDA-Approved Long-Acting _2-Adrenergic Receptor Agonists. Pediatrics published ahead of print October 24, 2011. [DOI: 10.1542/peds.2010-1720]
210. Miranda C, Busacker A, Balzar S, Trudeau J, Wenzel SE. Distinguishing severe asthma phenotypes: role of age at onset and eosinophilic inflammation. Journal of Allergy and Clinical Immunology 2004; Vol. 113, issue 1:101–8. [0091–6749]
211. Morrison KJ, Gao Y, Vanhoutte PM. Beta-adrenoceptors and the epithelial layer in airways. Life Sciences 1993; Vol. 52, issue 26:2123–30.
212. Nelson HS, Raine D, Doner HC, Posey WC. Subsensitivity to bronchodilator action of albuterol produced by chronic administration. American Review of Respiratory Disease 1977; Vol. 116, issue 5:871–8.
213. Ni Chroinin M, Greenstone IR, Ducharme FM. Addition of long-acting beta2-agonists to inhaled steroids as first line therapy for persistent asthma in steroid-naive adults and children. Cochrane Database of Systematic Reviews 2010, Issue 2. [DOI: 10.1002/14651858.CD005307]
214. Ni Chroinin M, Greenstone IR, Danish A, Magdolinos H, Masse V, Zhang X, et al. Long-acting beta2-agonists versus placebo in addition to inhaled corticosteroids in children and adults with chronic asthma. Cochrane Database of Systematic Reviews 2005, Issue 4. [DOI: 10.1002/14651858.CD005535]
215. Novartis. Foradil® Aerolizer® (formoterol fumarate inhalation powder) 12 mcg. NDA 20-831. Appendix 1 -List of pre-defined terms. http://www.fda.gov/OHRMS/DOCKETS/ac/05/briefing/2005-4148B1˙02˙02-Novartis-Appendix-1.pdf Accessed 4 June 2008.
216. Ordonez CL, Khashayar R, Wong HH, Ferrando RON, Wu R, Hyde DM, et al. Mild and moderate asthma is associated with airway goblet cell hyperplasia and abnormalities in mucin gene expression. American Journal of Respiratory and Critical Care Medicine 2001; Vol. 163, issue 2:517–23.
217. Palmqvist M, Ibsen T, Mellen A, Lotvall J. Comparison of the relative efficacy of formoterol and salmeterol in asthmatic patients. American Journal of Respiratory and Critical Care Medicine 1999; Vol. 160, issue 1:244–9.
218. Pearce N, Grainger J, Atkinson M, Crane J, Burgess C, Culling C, et al. Case-control study of prescribed fenoterol and death from asthma in New Zealand, 1977-81. Thorax 1990; Vol. 45, issue 3:170–5.
219. Pearce N BR, Crane J, Burgess C. Epidemiology of asthma mortality. Asthma and Rhinitis. Oxford: Blackwell Scientific, 2001:56–69.
220. Pearce N. Adverse Reactions: the Fenoterol Story. 1st Edition. Auckland: Auckland University Press, 2007:215. [9781869403744]
221. Phillips GD, Finnerty JP, Holgate ST. Comparative protective effect of the inhaled beta-2-agonist salbutamol (albuterol) on bronchoconstriction provoked by histamine, methacholine, and adenosine 5’-monophosphate in asthma. Journal of Allergy and Clinical Immunology 1990; Vol. 85, issue 4:755–62.
222. Salpeter SR, Buckley NS, Ormiston TM, Salpeter EE. Meta-analysis: effect of long-acting beta-agonists on severe asthma exacerbations and asthma-related deaths. Annals of Internal Medicine 2006;144(12):904–12.
223. Sears MR, Taylor DR, Print CG, Lake DC, Li QQ, Flannery EM, et al. Regular inhaled beta-agonist treatment in bronchial-asthma. Lancet 1990; Vol. 336, issue 8728: 1391–6.
224. Simonsson BG, Jacobs FM, Nadel JA. Role of autonomic nervous system and cough reflex in increased responsiveness of airways in patients with obstructive airway disease. Journal of Clinical Investigation 1967; Vol. 46, issue 11: 1812–8.
225. Nelson HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky PM, the SMART Study Group. The salmeterol multicenter asthma research trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 2006;129:15–26.
226. Speizer FE, Doll R, Heaf P. Observations on recent increase in mortality from asthma. British Medical Journal 1968; Vol. 1, issue 5588:335–9.
227. Stolley PD. Asthma mortality - why the United States was spared an epidemic of deaths due to asthma. American Review of Respiratory Disease 1972; Vol. 105, issue 6: 883–90.
228. Tattersfield AE. Current issues with beta(2)-adrenoceptor agonists - historical background. Clinical Reviews in Allergy and Immunology 2006; Vol. 31, issue 2–3:107–17.
229. Tonnel AB, Gosset P, Tillie-Leblond I. Characteristics of the inflammatory response in bronchial lavage fluids from patients with status asthmaticus. International Archives of Allergy and Immunology 2001; Vol. 124, issue 1–3: 267–71.
230. van der Woude HJ, Winter TH, Aalbers R. Decreased bronchodilating effect of salbutamol in relieving methacholine induced moderate to severe bronchoconstriction during high dose treatment with long acting beta(2) agonists. Thorax 2001; Vol. 56, issue 7: 529–35.
231. Van Noord JA, Smeets JJ, Raaijmakers JAM, Bommer AM, Maesen FPV. Salmeterol versus formoterol in patients with moderately severe asthma: onset and duration of action. European Respiratory Journal 1996; Vol. 9, issue 8:1684–8.
232. Vignola AM, Campbell AM, Chanez P, Bousquet J, Paullacoste P, Michel FB, et al. HLA-DR and ICAM-1 expression on bronchial epithelial-cells in asthma and chronic bronchitis. American Review of Respiratory Disease 1993; Vol. 148, issue 3:689–94.
233. Walters EH, Walters JAE, Gibson PW. Regular treatment with long acting beta agonists versus daily regular treatment with short acting beta agonists in adults and children with stable asthma. Cochrane Database of Systematic Reviews 2009, Issue 1. [DOI: 10.1002/14651858.CD003901]
234. Walters EH, Gibson PG, Lasserson TJ, Walters JAE. Long-acting beta2-agonists for chronic asthma in adults and children where background therapy contains varied or no inhaled corticosteroid. Cochrane Database of Systematic Reviews 2007, Issue 1. [DOI: 10.1002/14651858.CD001385.pub2]
235. Weber RW, Smith JA, Nelson HS. Aerosolized terbutaline in asthmatics - development of subsensitivity with longterm administration. Journal of Allergy and Clinical Immunology 1982; Vol. 70, issue 6:417–22.
236. Wiggs BR, Moreno R, Hogg JC, Hilliam C, Pare PD. A model of the mechanics of airway narrowing. Journal of Applied Physiology 1990; Vol. 69, issue 3:849–60.
237. Wilson JD, Sutherland DC, Thomas AC. Has the change to beta-agonists combined with oral theophylline increased cases of fatal asthma. Lancet 1981; Vol. 1, issue 8232: 1235–7.
238. Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE. Bronchodilator, cardiovascular, and hypokalemic effects of fenoterol, salbutamol, and terbutaline in asthma. Lancet 1990; Vol. 336, issue 8728:1396–9.
239. Woodruff PG, Dolganov GM, Ferrando RE, Donnelly S, Hays SR, Solberg OD, et al. Hyperplasia of smooth muscle in mild to moderate asthma without changes in cell size or gene expression. American Journal of Respiratory and Critical Care Medicine 2004; Vol. 169, issue 9:1001–6.
240. Yates DH, Kharitonov SA, Barnes PJ. An inhaled glucocorticoid does not prevent tolerance to the bronchoprotective effect of a long-acting inhaled beta(2)- agonist. American Journal of Respiratory and Critical Care Medicine 1996; Vol. 154, issue 6:1603–7.